Tag Archives: Acetylcholinesterase Inhibitors (AChEIs)

Review of Interventions Which May Potentially Delay Functional Decline in Persons With Dementia (BMJ Open)

Summary The authors examined 23 systematic reviews about the benefits of non-pharmacological, pharmacological and alternative therapies on activities of daily living (ADL) in people with dementia. Interventions thought to be effective (based on evidence sometimes judged to be “low quality”) … Continue reading

Posted in Commissioning, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Integrated Care, International, Management of Condition, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Personalisation, Pharmacological Treatments, Quick Insights, Systematic Reviews, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Pharmacological Treatments for Alzheimer’s Disease in Primary Care / Management of Cognitive Symptoms (DTB / Nursing Times)

Summary A Drug and Therapeutics Bulletin (DTB) article reviews the evidence concerning drugs prescribed for cognitive symptoms in Alzheimer’s Disease and discusses some issues in their prescription. Donepezil, galantamine and rivastigmine are licensed for mild to moderate Alzheimer’s Disease in … Continue reading

Posted in Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Management of Condition, Models of Dementia Care, NICE Guidelines, Pharmacological Treatments, Practical Advice, Quick Insights, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Use of NICE Appraised Medicines in the NHS in England (HSCIC)

Summary The Health and Social Care Information Centre (HSCIC) estimates that national figures for Alzheimer’s Disease medicine use have been underestimated by around five per cent. Section 3.1 in this report relates to Alzheimer’s Disease medicines: donepezil, galantamine, rivastigmine and memantine. … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), National, NHS, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (Health Technology Assessment)

[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 11, June 2012]. Summary The purpose of this Health Technology Assessment was to review and update guidance to the NHS in England and Wales … Continue reading

Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Researchers (mostly), Management of Condition, National, NHS, NIHR, Pharmacological Treatments, Proposed for Next Newsletter, Systematic Reviews, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Who Benefits Most From Cognitive Stimulation Therapy (CST)? (University College London)

[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 11, June 2012]. Summary The study investigated the factors which predict who is likely to benefit from Cognitive Stimulation Therapy (CST). Two hundred and seventy-two … Continue reading

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Management of Condition, Non-Pharmacological Treatments, Universal Interest | Tagged , , , , , , , , , , , | Leave a comment